Carlsmed Leads Competitors in Personalized Spine Surgery Solutions

Got story updates? Submit your updates here. ›

Carlsmed (NASDAQ:CARL) is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions. The company's aprevo Technology Platform consists of AI-enabled software, custom-designed interbody implants, and single-use surgical instruments. Compared to traditional spine fusion surgery, the aprevo Technology Platform is designed to address limitations in pre-operative planning, implant fit, and post-operative data collection to improve alignment and reduce the need for revision surgeries.

Why it matters

Carlsmed's personalized approach aims to address the limitations of traditional spine fusion surgery, which can lead to poor clinical outcomes and high revision rates. By providing customized surgical plans and implants, the aprevo Technology Platform seeks to optimize patient outcomes and reduce the significant economic burden associated with revision surgeries.

The details

The aprevo Technology Platform utilizes AI-enabled algorithms and 3D modeling to develop personalized digital surgical plans and custom-designed interbody implants for each patient's unique anatomy and pathology. This contrasts with traditional spine fusion, which relies on stock implants that often fail to match patient anatomy. Carlsmed's platform also supports post-operative data collection to inform future surgical planning. The aprevo Technology Platform is FDA-cleared for lumbar fusion and Carlsmed is developing it for cervical fusion as well.

• In November 2024, Carlsmed received FDA 510(k) clearance for its aprevo interbody implants for cervical interbody fusion surgeries.
• In 2025, Carlsmed plans to continue building its aprevo Technology Platform for cervical fusion procedures by pursuing additional clearances for advancements to its cervical software platform and personalized plating solutions.
• Carlsmed expects to commercialize the aprevo Technology Platform for cervical fusion surgery in 2026, pending necessary additional clearances.

What’s next

Carlsmed plans to continue growing its commercial infrastructure, including its direct sales team and independent sales agents, to expand market access for the aprevo Technology Platform. The company is also conducting a 338-patient study to track clinical outcomes from procedures using its platform.